CALGARY, ALBERTA–(Marketwired – Dec. 9, 2015) – Quikflo Health Inc. (“Quikflo” or the “Company“) (TSX VENTURE:QF) is pleased to announce that the cover of the December issue of the journal Stroke features the article, “Time-Dependent Computed Tomographic Perfusion Thresholds for Patients With Acute Ischemic Stroke,” based on pioneering research led by the University of Calgary and the co-inventors of Quikflo. This ground breaking research demonstrates the feasibility and reproducibility of using CT Perfusion to predict the growth in infarct size within a stroke patient’s brain over time. Quikflo is building technologies that incorporate insights like these to help medical professionals triage stroke patients around the world better and faster.
Dr. Bijoy Menon, co-Founder of Quikflo and member of the Calgary Stroke Program, said “The innovations developed at the Calgary Stroke Program, many of which were implemented in the recent ESCAPE trial, are already improving outcomes for stroke patients here and around the world. We believe that the knowledge gaps in stroke triage that are shared by many hospitals worldwide are solvable, particularly by a technology solution that reads a patient’s CT scan accurately and rapidly. We founded Quikflo to resolve that gap and bring the Calgary Stroke Program’s expertise to every hospital, everywhere.”
“We are very pleased to see the Quikflo technology featured prominently in this prestigious international journal,” said Ken Porter, vice-president, Intellectual Property Management, Innovate Calgary. “The partnership between the University of Calgary and Quickflo is expediting the pace of technology development, which will ultimately improve outcomes for patients worldwide. Innovate Calgary works closely with university inventors to match them with management and investor teams who can accelerate knowledge translation from the bench to the clinic, and Quickflo continues to be a shining example of how these partnerships can benefit public health.”
“Our mission is to arm medical professionals with the information they need to make decisions quickly and accurately, and thereby minimize the global impact of stroke,” said Vinny Jindal, President and Chief Executive Officer of Quikflo. “Our first software product – Fast Accurate Stroke Triage, or FAST – makes the world-renowned clinical expertise of the Calgary Stroke Program available to every medical center that sees stroke patients, anywhere in the world, to help create better outcomes for patients, hospitals, and healthcare systems.”
Quikflo Health is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.
About Innovate Calgary
As a leading technology transfer and commercialization centre, Innovate Calgary works closely with startups, entrepreneurs, researchers and investors from the advanced tech sector to take innovation and ideas to the next stage of growth. Innovate Calgary has been successfully contributing to the growth and acceleration of the advanced technology sector for more than 30 years. Our integrated approach to commercialization focuses on facilitating connections among stakeholders and offering a comprehensive range of programs and services to achieve success. To learn more visit: innovatecalgary.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary and Forward-Looking Statements
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the Company’s corporate strategy. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the suitability of the key members of ongoing management and the board of directors, the commercial opportunities available to the Company based on the technology acquired, and the ability of the Company to obtain sufficient funds to commercialize any product. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete suitable acquisitions to further the Company’s growth, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on www.sedar.com. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive and additional risks and uncertainties is set forth in the circular.
The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
President and CEO